AstraZeneca PLC $AZN Shares Bought by Chilton Capital Management LLC

Chilton Capital Management LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 7.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 397,613 shares of the company’s stock after acquiring an additional 26,781 shares during the period. Chilton Capital Management LLC’s holdings in AstraZeneca were worth $27,785,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its stake in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after purchasing an additional 289 shares during the period. Richardson Financial Services Inc. increased its holdings in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of AstraZeneca during the 1st quarter valued at approximately $29,000. Maseco LLP purchased a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $34,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of AstraZeneca in the 1st quarter worth approximately $37,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Friday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Trading Down 0.1%

NASDAQ AZN opened at $83.29 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. AstraZeneca PLC has a one year low of $61.24 and a one year high of $86.57. The company’s 50 day moving average price is $80.87 and its 200 day moving average price is $74.41. The firm has a market capitalization of $258.32 billion, a price-to-earnings ratio of 31.31, a PEG ratio of 1.54 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s revenue was up 16.1% on a year-over-year basis. During the same period last year, the business posted $1.24 EPS. On average, sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a $0.505 dividend. This represents a dividend yield of 200.0%. The ex-dividend date was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is presently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.